Viveve Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle East, Latin America, and internationally. The company was founded in 2005 and is headquartered in Englewood, Colorado.
IPO Year:
Exchange: NASDAQ
Website: viveve.com
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Alliance Global Partners initiated coverage of Viveve Medical with a rating of Buy
Alliance Global Partners initiated coverage of Viveve Medical with a rating of Buy and set a new price target of $10.75
15-12G - VIVEVE MEDICAL, INC. (0000879682) (Filer)
EFFECT - VIVEVE MEDICAL, INC. (0000879682) (Filer)
EFFECT - VIVEVE MEDICAL, INC. (0000879682) (Filer)
EFFECT - VIVEVE MEDICAL, INC. (0000879682) (Filer)
EFFECT - VIVEVE MEDICAL, INC. (0000879682) (Filer)
EFFECT - VIVEVE MEDICAL, INC. (0000879682) (Filer)
EFFECT - VIVEVE MEDICAL, INC. (0000879682) (Filer)
EFFECT - VIVEVE MEDICAL, INC. (0000879682) (Filer)
S-8 POS - VIVEVE MEDICAL, INC. (0000879682) (Filer)
POS AM - VIVEVE MEDICAL, INC. (0000879682) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)
4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)
4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)
4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)
4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)
4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)
4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)
4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)
4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)
4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)
Fastest customizable press release news feed in the world
Study's primary efficacy endpoint was not achieved at 12 months post-treatmentCompany has implemented a reduction in forceCompany will seek strategic alternatives and will be delisted from Nasdaq ENGLEWOOD, CO / ACCESSWIRE / January 17, 2023 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today announced topline result from the U.S. Pivotal PURSUIT clinical trial. PURSUIT was a multicenter, randomized, double-blinded, sham-controlled U.S. study to evaluate the safety and efficacy of the Viveve treatment for SUI in women. The results were obtained by the company on Friday evening, Janu
Topline results of the 12-month primary efficacy endpoint anticipated in January 2023Positive results may support a de novo marketing application for a new U.S. indication for treatment of stress urinary incontinence in womenENGLEWOOD, CO / ACCESSWIRE / December 15, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and treatment of female stress urinary incontinence, today announced the completion of final 12-month post-treatment follow-up visits in its landmark U.S. PURSUIT clinical trial for the treatment of stress urinary incontinence (SUI) in women. A total of 415 patients were enrolled in the trial, and 342 patients completed 12-month foll
Patent further strengthens Viveve's novel dual-energy technology intellectual property portfolio as company plans for completion of pivotal PURSUIT clinical trialENGLEWOOD, CO / ACCESSWIRE / December 1, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11511110 covering Viveve's treatment to address SUI in women. The issuance of the new patent strengthens the Company's intellectual property portfolio in advance of the planned completion of its U.S. pivotal PURSUIT clinical trial by the e
Total revenue of $1.7 million in Q3 including sale of 3,100 disposable treatment tipsPURSUIT clinical trial completion expected by year-endConference call to be hosted by Company at 5:00 PM ET todayENGLEWOOD, CO / ACCESSWIRE / November 10, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today reported financial results for the quarter ended September 30, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today."During the third quarter of 2022, we continued to make great progress in the final phase of our pivotal U.S. PURSUIT clinical trial fo
ENGLEWOOD, CO / ACCESSWIRE / October 27, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that it will report its third quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, November 10, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.The third quarter 2022 results conference call may be accessed on Thursday, November 10th at 5:00 PM ET by dialing 1-833-255-2833 (domestic) or 1-412-902-6728 (international) or via live webcast at https://event.choruscall.com/mediaframe/we
Patent issuance further strengthens Viveve's intellectual property portfolio for the treatment of female stress urinary incontinenceENGLEWOOD, CO / ACCESSWIRE / October 4, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today announced the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application 16/454,578 covering Viveve's unique dual-energy treatment to address SUI in women. The pending issuance of the new SUI patent further strengthens the Company's intellectual property portfolio in advance of the planned com
New branding reflects Company's vision to be the leader in the treatment of Stress Urinary Incontinence in WomenCompletion of PURSUIT follow-up visits anticipated by the end of 2022 with topline results expected shortly thereafterENGLEWOOD, CO / ACCESSWIRE / September 27, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today announced the launch of a company-wide rebranding initiative that will include content and new graphic elements related to the treatment of SUI in women. The rebranding is being completed in advance of the planned reporting of topline results from Viveve's piv
ENGLEWOOD, CO / ACCESSWIRE / September 22, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the Ladenburg Thalmann Healthcare Conference, September 29, 2022, in New York City. Mr. Durbin will deliver the Viveve corporate presentation and provide an update on progress of the Company's SUI clinical development program. He will also meet with investment community members during the conference.Event: Ladenburg Thalmann Healthcare ConferenceThursday, September 29, 2022Webcast: Thursday, September 29th, 8:30 AM ETTh
ENGLEWOOD, CO / ACCESSWIRE / September 15, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the Alliance Global Partners Virtual MedTech Conference, September 21, 2022. Mr. Durbin will provide an update on Viveve's operations including progress of its SUI clinical development program and will meet with investment community members during the virtual conference.Event:Alliance Global Partners Virtual MedTech ConferenceWednesday, September 21, 2022About ViveveViveve Medical, Inc. is a medical technology company f
ENGLEWOOD, CO / ACCESSWIRE / September 1, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the H.C. Wainwright 24th Annual Global Investment Conference, September 12 - 14, 2022. Mr. Durbin will deliver the Viveve corporate presentation and meet with investment community members during the hybrid conference.Event: H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 12 - 14, 2022Presentation Webcast: Monday, September 12, 2022, 7:00 AM ETThe corporate presentation will be webcast on the Investors s
Live finance-specific insights
Total revenue of $1.7 million in Q3 including sale of 3,100 disposable treatment tipsPURSUIT clinical trial completion expected by year-endConference call to be hosted by Company at 5:00 PM ET todayENGLEWOOD, CO / ACCESSWIRE / November 10, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today reported financial results for the quarter ended September 30, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today."During the third quarter of 2022, we continued to make great progress in the final phase of our pivotal U.S. PURSUIT clinical trial fo
ENGLEWOOD, CO / ACCESSWIRE / October 27, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that it will report its third quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, November 10, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.The third quarter 2022 results conference call may be accessed on Thursday, November 10th at 5:00 PM ET by dialing 1-833-255-2833 (domestic) or 1-412-902-6728 (international) or via live webcast at https://event.choruscall.com/mediaframe/we
Total revenue of $1.8 million in Q2 including sale of 2,850 disposable treatment tipsPURSUIT clinical trial follow-up visit completion anticipated by year endConference call to be hosted by Company at 5:00 PM ET todayENGLEWOOD, CO / ACCESSWIRE / August 11, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today reported financial results for the quarter ended June 30, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today."During the second quarter of 2022, we continued to advance our stress urinary incontinence (SUI) clinical development program. We
ENGLEWOOD, CO / ACCESSWIRE / July 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that it will report its second quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, August 11, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.The second quarter 2022 results conference call may be accessed on Thursday, August 11th at 5:00 PM ET by dialing 1-833-255-2833 (domestic) or 1-412-902-6728 (international) or via live webcast at https://event.choruscall.com/mediaframe/webcast
Total revenue of $1.6 million in Q1 including sale of 2,750 consumable treatment tipsPURSUIT trial top-line results anticipated at end of 2022Conference call to be hosted by Company at 5:00 PM ET todayENGLEWOOD, CO / ACCESSWIRE / May 12, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported financial results for the quarter ended March 31, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today."During the first quarter of 2022, we continued the focus on advancing our stress urinary incontinence (SUI) clinical development program. We remain on track to complete all patient follow-up vi
ENGLEWOOD, CO / ACCESSWIRE / April 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its first quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, May 12, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day. The first quarter 2022 results conference call may be accessed on Thursday, May 12th at 5:00 PM ET by dialing 1-833-255-2833 (domestic) or 1-412-902-6728 (international) or via live webcast at https://services.choruscall.com/mediaframe/webcast.html?webcastid=kTDfnY3F. Participants may also
Reported total revenue for year end 2021 of $6.4 million representing 17% year-over-year growthEnrollment completed in U.S. pivotal PURSUIT trial for stress urinary incontinence and 12-month post treatment follow-up visits underwayPURSUIT top-line results anticipated at end of 2022Conference call to be hosted by Company at 5:00 PM ET todayENGLEWOOD, CO / ACCESSWIRE / March 17, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported financial results for the year ended December 31, 2021. The Company will provide a corporate update on its scheduled conference call at 5:00 PM ET today."I am extremely pleased with the milestones
ENGLEWOOD, CO / ACCESSWIRE / March 3, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its full year 2021 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, March 17, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.The full year 2021 results conference call may be accessed on Thursday, March 17th at 5:00 PM ET by dialing 1-833-255-2833 (domestic) or 1-412-902-6728 (international) or via live webcast at https://services.choruscall.com/mediaframe/webcast.html?webcastid=NZykfofx. Participants may also registe
Total revenue of $1.6M reported for Q3Pivotal SUI PURSUIT trial enrollment nears completion - randomizations on-track for completion in Q4ENGLEWOOD, CO / ACCESSWIRE / November 11, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported financial results for the quarter ended September 30, 2021, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today. The Company's 10-Q documents will be filed on Friday, November 12, 2021, when the U.S. Securities and Exchange Commission reopens following the Veterans Day holiday."During the third quarter of 2021, we continued to make great progress in advancin
ENGLEWOOD, CO / ACCESSWIRE / November 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its third quarter 2021 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, November 11, 2021. The Company will hold a conference call and webcast at 5:00 PM ET the same day.The Company's 10-Q documents will be filed on Friday, November 12, 2021, when the U.S. Securities and Exchange Commission reopens following the Veterans Day holiday.The third quarter 2021 results conference call may be accessed on Thursday, November 11th at 5:00 PM ET by dialing 1-833-
This live feed shows all institutional transactions in real time.
SC 13G/A - VIVEVE MEDICAL, INC. (0000879682) (Subject)
SC 13G/A - VIVEVE MEDICAL, INC. (0000879682) (Subject)
SC 13G/A - VIVEVE MEDICAL, INC. (0000879682) (Subject)